In this podcast, Stephen Rose, MD, president and CEO of Houston Breast Imaging and a principal investigator of the 3-D tomosynthesis clinical trials in 2010, discusses the benefits of the new technology and what his practice learned when implementing the screening program.
[[{"type":"media","view_mode":"media_crop","fid":"11554","attributes":{"alt":"Stephen Rose","class":"media-image media-image-left","id":"media_crop_8501769795264","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"218","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: left;","title":" ","typeof":"foaf:Image"}}]]In February 2011, the FDA approved the first X-ray mammography system that provides 3-D images for breast cancer screening and diagnosis, Hologic’s Selenia Dimensions. The 3-D tomosynthesis is being offered in fewer than two dozen locations in the U.S., and among them is Houston Breast Imaging in Texas.
In this podcast, Stephen Rose, MD, president and CEO of Houston Breast Imaging and a principal investigator of the 3-D tomosynthesis clinical trials in 2010, discusses the benefits of the new technology and what his practice learned when implementing the screening program. .
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.